Angivas MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.
Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β-oxidation. This is made possible by selective inhibition of an enzyme of fatty acid β-oxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in reduction in fatty acid oxidation & stimulation of glucose oxidation.
Trimetazidine is indicated in prophylactic treatment of episodes of angina pectoris and sequelae of infarction, heart failure. Adjuvant symptomatic treatment of vertigo and tinnitus. Adjuvant treatment of the decline in visual acuity and visual field disturbances presumably of vascular origin.
Angivas MR Tablet: 1 tablet at mealtimes in the morning and evening.
Child: Not recommended.
For patients with impaired renal function (creatinine clearance between 15 and 90 mL/min), the starting dose is one tablet twice daily respectively in the morning and in the evening.
*Prescription only*
The clinical studies of Trimetazidine showed no evidence of interactions with other drugs, particularly in elderly patients.
Pregnancy: No teratogenic effect was seen in animal studies. In the absence of clinical data, a risk of birth defect induction cannot be excluded. Consequently, as a precaution it is best not to prescribe the drug during pregnancy.
This drug is not a curative treatment for angina attacks, nor is it indicated as an initial treatment for unstable angina, or myocardial infarction. It should not be used in the pre-hospital phase or during the first days of hospitalization.
In the event of an angina attack, the coronaropathy should be reevaluated and an adaptation of the treatment considered (drug treatment and possibly revascularisation).
In patients with renal failure, prescription of Trimetazidine is not recommended if the creatinine clearance is lower than 15 ml/min (in the absence of specific studies).
In patients with severe hepatic failure, in the absence of specific studies, prescription of Trimetazidine is not recommended.
Overdose:
Very limited information is available on Trimetazidine overdose. Treatment should be symptomatic.
Store at below 30°C in a dry place protected from light. Keep out of reach of children.